CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational conditionally activated therapeutics based on
its Probody® technology platform, today announced the appointment
of Alan Ashworth, Ph.D., FRS, a world-renowned expert in cancer
research and a global leader in cancer therapy development, to the
company’s board of directors.
“It is a privilege to welcome Alan to our
board,” commented Sean McCarthy, D.Phil., president, chief
executive officer and chairman of CytomX Therapeutics. “As a highly
distinguished cancer researcher with a deep emphasis on
translational sciences throughout his career, Alan brings
wide-ranging experience to CytomX which will be enormously valuable
as we advance our clinical pipeline towards key Phase 2 inflection
points and continue to lead the field of protease-activated,
conditional antibody therapeutics.”
A recognized and accomplished cancer researcher,
Dr. Ashworth was a key part of the team that identified the BRCA2
breast cancer susceptibility gene, now commonly used to identify
and stratify individuals who are at increased risk of developing
breast and ovarian cancer. His research also led to the development
of poly (ADP-ribose) polymerase (PARP) inhibitors to exploit the
unique sensitivity of BRCA1- and 2-related tumor cells to PARP
inhibition using the concept of synthetic lethality.
“It is my pleasure to join CytomX’s board as the
Company continues to innovate and advance its broad and diverse
pipeline of potential first-in-class product candidates,” said Dr.
Ashworth. “I look forward to working with the entire board and the
executive team to help advance CytomX’s vision of bringing more
effective therapies to cancer patients.”
Dr. Ashworth is president, University of
California, San Francisco (UCSF) Helen Diller Family Comprehensive
Cancer Center; senior vice president for cancer services, UCSF
Health; a professor of medicine, division of hematology/oncology,
department of medicine; and E. Dixon Heise Distinguished Professor
in Oncology. Previously, he was chief executive officer of the
Institute of Cancer Research and director of the Breakthrough
Breast Cancer Center in London, U.K.
Dr. Ashworth is an elected member of European
Molecular Biology Organization, the Academy of Medical Sciences,
and a Fellow of the Royal Society. He has received a number of
scientific prizes and awards, including The European Society of
Medical Oncology Lifetime Achievement Award, the David T. Workman
Memorial Award of the Samuel Waxman Cancer Research Foundation, the
Meyenburg Foundation’s Cancer Research Award, the Basser Global
Prize, the Genetics Society Medal, and the Susan G Komen Brinker
award.
Dr. Ashworth received his Ph.D. in biochemistry
from University College London, U.K., and his B.Sc. in chemistry
and biochemistry from Imperial College of Science and Technology,
University of London, U.K.
About CytomX
TherapeuticsCytomX is a clinical-stage, oncology-focused
biopharmaceutical company with a vision of transforming lives with
safer, more effective therapies. We are developing a novel class of
investigational conditionally activated therapeutics, based on our
Probody® technology platform, for the treatment of cancer. CytomX
has strategic drug discovery and development collaborations with
AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Probody therapeutics are conditionally activated
biologics designed to remain inactive until they are activated by
proteases in the tumor microenvironment. As a result, Probody
therapeutics are intended to bind selectively to tumors and
decrease binding to healthy tissue, to minimize toxicity and
potentially create safer, more effective therapies. As leaders in
the field, our innovative technology is designed to turn previously
undruggable targets into druggable targets and to enable more
effective combination therapies. CytomX and its partners, comprised
of leading biotechnology and pharmaceutical companies, have
developed a robust pipeline of potential first-in-class therapeutic
candidates against novel, difficult to drug targets and potential
best-in-class immunotherapeutic candidates against clinically
validated targets. The CytomX clinical-stage pipeline comprises
five assets, four of which are in Phase 2 clinical studies.
First-in-class product candidates against previously undruggable
targets include a CD166-targeting conditionally activated
antibody-drug conjugate wholly owned by CytomX (praluzatamab
ravtansine, CX-2009) and a CD71-targeting conditionally activated
antibody-drug conjugate partnered with AbbVie (CX-2029). CD166 and
CD71 are among cancer targets that are considered to be
inaccessible to conventional antibody-drug conjugates due to their
presence on many healthy tissues. The CytomX clinical-stage
pipeline also includes cancer immunotherapeutic candidates against
validated targets such as the CTLA-4-targeting Probodies,
BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and
our wholly-owned conditionally activated anti-PD-L1 antibody,
pacmilimab (CX-072). For additional information about CytomX
Therapeutics, visit www.cytomx.com and follow us on LinkedIn and
Twitter.
CytomX Therapeutics Forward-Looking
StatementsThis press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements. Accordingly, you should
not rely on any of these forward-looking statements, including
those relating to the potential benefits, safety and efficacy or
progress of CytomX’s or any of its collaborative partners’ product
candidates, including praluzatamab ravtansine (CX-2009), CX-2029,
BMS-986249, BMS-986288, and pacmilimab (CX-072), the potential
benefits or applications of CytomX’s Probody platform technology,
CytomX’s ability to develop and advance product candidates into and
successfully complete clinical trials, including the ongoing and
planned clinical trials of praluzatamab ravtansine, CX-2029,
BMS-986249, BMS-986288, and pacmilimab, and the timing of the
commencement of clinical trials, initial data and other development
milestones. Risks and uncertainties that contribute to the
uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology;
CytomX’s clinical trial product candidates are in the initial
stages of clinical development and its other product candidates are
currently in preclinical development, and the process by which
preclinical and clinical development could potentially lead to an
approved product is long and subject to significant risks and
uncertainties, including the risk that the COVID-19 worldwide
pandemic may continue to negatively impact the business, research
and clinical operations of CytomX or its partners, including the
development of preclinical drug candidates due to delays in and
disruption of research activities and the development of clinical
drug candidates due to delays in or disruption of clinical trials,
including impacts on the enrollment of patients in clinical trials
or other clinical trial disruptions; the possibility that the
results of early clinical trials may not be predictive of future
results; the possibility that CytomX’s clinical trials will not be
successful; the possibility that current preclinical research may
not result in additional product candidates; CytomX’s dependence on
the success of praluzatamab ravtansine, CX-2029, BMS-986249,
BMS-986288, and pacmilimab; CytomX’s reliance on third parties for
the manufacture of the Company’s product candidates; and possible
regulatory developments in the United States and foreign
countries. Additional applicable risks and uncertainties include
those relating to our preclinical research and development,
clinical development, and other risks identified under the heading
“Risk Factors” included in CytomX’s Quarterly Report on Form 10-Q
filed with the SEC on August 5, 2021. The
forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
Investor Contact:Chau Cheng,
PhD MBAVP, Investor Relations & Corp.
Communicationsccheng@cytomx.com Direct: (650) 273-4999
Media Contact:Bret
CoonsDirector, Corporate Communicationsbcoons@cytomx.com Direct:
(650) 528 2929
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024